Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Retirement Systems of Alabama

Retirement Systems of Alabama reduced its position in Edwards Lifesciences Co. (NYSE:EW) by 0.6% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 132,178 shares of the medical research company’s stock after selling 751 shares during the quarter. Retirement Systems of Alabama’s holdings in Edwards Lifesciences were worth $8,722,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently added to or reduced their stakes in EW. Purus Wealth Management LLC grew its holdings in Edwards Lifesciences by 5.2% in the second quarter. Purus Wealth Management LLC now owns 3,212 shares of the medical research company’s stock valued at $297,000 after purchasing an additional 160 shares during the period. Busey Bank grew its stake in Edwards Lifesciences by 1.9% in the 2nd quarter. Busey Bank now owns 8,838 shares of the medical research company’s stock valued at $816,000 after acquiring an additional 165 shares during the period. JFS Wealth Advisors LLC increased its holdings in Edwards Lifesciences by 31.1% in the 3rd quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock worth $46,000 after acquiring an additional 166 shares in the last quarter. Seascape Capital Management increased its holdings in Edwards Lifesciences by 0.5% in the 3rd quarter. Seascape Capital Management now owns 32,989 shares of the medical research company’s stock worth $2,177,000 after acquiring an additional 174 shares in the last quarter. Finally, Meiji Yasuda Asset Management Co Ltd. lifted its holdings in Edwards Lifesciences by 1.2% during the second quarter. Meiji Yasuda Asset Management Co Ltd. now owns 15,341 shares of the medical research company’s stock valued at $1,417,000 after purchasing an additional 184 shares in the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the company. Citigroup lifted their price objective on Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Stifel Nicolaus upped their target price on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the stock a “hold” rating in a report on Thursday, December 5th. JPMorgan Chase & Co. boosted their price target on shares of Edwards Lifesciences from $72.00 to $78.00 and gave the stock a “neutral” rating in a research report on Friday, October 25th. Truist Financial reiterated a “hold” rating and issued a $78.00 price objective (up previously from $70.00) on shares of Edwards Lifesciences in a report on Thursday, December 5th. Finally, Wells Fargo & Company lowered their target price on Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating on the stock in a report on Monday, September 9th. Sixteen equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $79.40.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $69.51, for a total transaction of $347,550.00. Following the sale, the vice president now directly owns 46,936 shares in the company, valued at $3,262,521.36. This represents a 9.63 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, VP Daniel J. Lippis sold 2,500 shares of the business’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $74.08, for a total transaction of $185,200.00. Following the completion of the transaction, the vice president now owns 23,189 shares of the company’s stock, valued at approximately $1,717,841.12. This trade represents a 9.73 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 37,500 shares of company stock worth $2,508,350 over the last ninety days. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Trading Up 0.3 %

NYSE EW opened at $74.15 on Wednesday. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12. The stock has a market capitalization of $43.73 billion, a P/E ratio of 10.70, a PEG ratio of 3.63 and a beta of 1.12. The firm’s 50-day moving average is $69.72 and its two-hundred day moving average is $73.71. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, hitting the consensus estimate of $0.67. The firm had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.57 billion. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The business’s revenue for the quarter was up 8.9% compared to the same quarter last year. During the same period in the prior year, the business posted $0.59 EPS. On average, sell-side analysts anticipate that Edwards Lifesciences Co. will post 2.56 earnings per share for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.